TNFRSF17 and B-cell chronic lymphocytic leukemia: These results imply that despite low BCMA expression on primary CLL cells, these cells can be lysed by teclistamab upon coculture with autologous T cells, but leads to lower cytotoxicity compared with multiple myeloma.